The global molybdenum 99 market is experiencing steady growth due to increasing demand for nuclear medicine procedures, rising prevalence of chronic diseases, and growing adoption of advanced diagnostic imaging technologies. The global molybdenum 99 market size was valued at USD 4.14 billion in 2025 and is projected to grow from USD 4.37 billion in 2026 to USD 6.70 billion by 2034, registering a CAGR of 5.50% during the forecast period (2026–2034).

The market expansion is driven by the growing utilization of technetium-99m in diagnostic imaging procedures, increasing investments in healthcare infrastructure, and rising demand for early disease detection. Molybdenum-99 serves as the parent isotope of technetium-99m, which is widely used in nuclear medicine for imaging cardiovascular diseases, cancer, neurological disorders, and other medical conditions.

Market Drivers

One of the primary factors driving the molybdenum 99 market is the increasing prevalence of chronic diseases worldwide. The growing burden of cancer, cardiovascular disorders, and neurological conditions has significantly increased the demand for advanced diagnostic imaging procedures that rely on technetium-99m.

Another significant growth driver is the expansion of nuclear medicine applications. Healthcare providers are increasingly utilizing radioisotope-based diagnostic techniques due to their accuracy, efficiency, and ability to support early disease diagnosis and treatment planning.

The growing investments in healthcare infrastructure and nuclear medicine facilities are also contributing to market growth. Governments and healthcare organizations are focusing on improving access to advanced diagnostic technologies, thereby supporting the demand for molybdenum-99.

Market Challenges

Despite favorable growth prospects, the molybdenum 99 market faces several challenges. One major restraint is the limited number of nuclear reactors available for molybdenum-99 production, which can create supply chain vulnerabilities and periodic shortages.

Another challenge is the high regulatory requirements associated with the production, transportation, and handling of radioactive materials. Compliance with stringent safety standards increases operational complexity and costs for manufacturers.

Additionally, the short half-life of molybdenum-99 requires efficient logistics and distribution networks, making supply chain management a critical challenge for market participants.

Market Segmentation

By Production Method:

• Uranium-235 Fission
• Neutron Activation

The uranium-235 fission segment dominates the market due to its ability to produce high yields of molybdenum-99 for commercial nuclear medicine applications.

By Application:

• Diagnostic Imaging
• Cancer Detection
• Cardiology
• Neurology
• Others

Diagnostic imaging accounts for the largest market share owing to the extensive use of technetium-99m in single-photon emission computed tomography (SPECT) procedures.

By End User:

• Hospitals
• Diagnostic Imaging Centers
• Research Institutes
• Nuclear Medicine Facilities

Hospitals represent the largest end-user segment due to the increasing number of nuclear imaging procedures performed for disease diagnosis and monitoring.

By Isotope Usage:

• Technetium-99m Generators
• Research Applications
• Industrial Applications

Technetium-99m generators hold a significant market share as they serve as the primary source of radiopharmaceuticals used in medical imaging procedures.

Regional Insights

North America dominates the global molybdenum 99 market due to advanced healthcare infrastructure, widespread adoption of nuclear medicine procedures, and strong presence of leading radioisotope suppliers.

Europe represents a significant market supported by established nuclear medicine programs, increasing healthcare expenditure, and strong government support for medical imaging technologies.

Asia-Pacific is expected to witness substantial growth during the forecast period owing to rising healthcare investments, increasing prevalence of chronic diseases, and expanding access to nuclear medicine services in countries such as China, India, Japan, and South Korea.

Latin America, the Middle East, and Africa are emerging markets driven by improving healthcare infrastructure, growing awareness of advanced diagnostic procedures, and increasing investments in medical imaging facilities.

Key Players Analysis

The molybdenum 99 market is highly competitive, with leading companies focusing on production capacity expansion, supply chain optimization, and technological advancements to strengthen their market positions. Key companies operating in the market include:

• Curium Pharma
• NorthStar Medical Radioisotopes, LLC
• BWX Technologies, Inc.
• NTP Radioisotopes SOC Ltd.
• Australian Nuclear Science and Technology Organisation (ANSTO)
• Shine Technologies LLC
• Institute of Isotopes Co., Ltd.
• Rosatom State Atomic Energy Corporation
• RadioMedix, Inc.
• Mallinckrodt Pharmaceuticals

These companies continue investing in alternative production technologies, reactor modernization, and isotope supply reliability to strengthen their competitive positioning in the global molybdenum 99 market.

For Detailed Insights, Visit:

https://straitsresearch.com/report/global-molybdenum-99-market

About Us

Straits Research is a leading research and intelligence organization specializing in research, analytics, and advisory services, along with providing business insights and comprehensive market research reports across multiple industries.

Contact Us

Email: sales@straitsresearch.com

Tel: +1 646 905 0080 (U.S.), +44 203 695 0070 (U.K.)